- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Public complaint alleged Janssen failed to disclose Incivo (telaprevir) trial results. Panel found the relevant J&J-sponsored UK-involved study was published within the…
Public complaint about trial transparency data. PMCPA found a breach for delayed disclosure of one Onglyza UK-involved trial (Clauses 21.3 and 9.1,…
A consultant presented a slide calling Emerade 500mcg ‘New Design’ after Bausch & Lomb had given undertakings not to describe the product…
Janssen admitted a Crohn’s awareness campaign sent to UK gastroenterologists promoted ustekinumab for an unlicensed indication and was not UK-certified. PMCPA found…
AMCo admitted a rep sent an unapproved promotional email for Lutrate containing a confusing, unscientifically valid and unsubstantiated claim. PMCPA found breaches…
Anonymous consultant alleged BMS promoted Opdivo pre-licence/unlicensed (lymphoma) via MPs and entertained them. Panel had concerns about MP interactions but found allegations…
Anonymous complaint about a nurse-led consultancy. Panel found no proven breach for therapy review grants, but ruled breaches after an email implied…
PMCPA found Novo Nordisk in breach for a patient video implying a once-daily injection ‘utterly transformed’ life (unfounded hope), unclear sponsorship disclosure…
PV consultant alleged off-label exacerbation-risk promotion for Ultibro. Panel found breaches for a FLAME “business card” and unclear GOLD briefing, including breach…
Media reports triggered a PMCPA case about a Germany meeting for UK NHS payors. The Panel ruled it wasn’t a genuine advisory…
PMCPA ruled Janssen promoted unlicensed guselkumab via a BAD 2017 symposium that lacked genuine two-way scientific exchange and appeared product-focused. Breaches of…
Complaint alleged a Sanofi-Aventis rep misrepresented ADA/EASD guidance for Lantus and confused Acomplia study data/positioning in type 2 diabetes. Panel could not…
AstraZeneca representative used a private GP consultation (for his child) to leave Symbicort promotional material on the doctor’s desk. PMCPA ruled breaches…
Lilly challenged a Levemir advertorial in Pulse. PMCPA found the “Weight advantages with Levemir” section misleading/ambiguous and inconsistent with the SPC. Breaches…
Anonymous alleged AstraZeneca funded inappropriate hospitality at a Midlands Psychiatric Research Group meeting. Panel found the event primarily educational and no evidence…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.